Skip to content
Company
Company overview→Strategy→Management & leadership→
Business
Business overview→MRNA Scientific→Chemrex Corporation→Fidelion Diagnostics*→Ascension Innovation*→CogniAI healthcare license*→

* Investments and partnerships; not operating subsidiaries.

Technology
Technology overview→Blood-based genomic screening→VitaGuard MRD→
Newsroom
Latest news→Press releases→Events & presentations→
Investors
Investor overview→Financial information→SEC filings→Corporate governance→Stock & shareholder information→Investor contact→
Contact
Nasdaq:BGLC

Legal and disclosures

Important website information.

Company information is current as of July 24, 2026 unless another date is stated. Financial information is presented as of the periods specified in BGLC's SEC filings.

Forward-looking statements

This website contains “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements include statements concerning BioNexus Gene Lab Corp.'s plans, objectives, strategies and expectations relating to product development, technical and clinical validation, regulatory activities, commercialization, manufacturing, market expansion, acquisitions, financing, costs and future operating performance. Words such as “may,” “will,” “expect,” “intend,” “plan,” “believe,” “target,” “objective,” “potential,” “future” and similar expressions may identify forward-looking statements.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include those described in BGLC's most recent Annual Report on Form 10-K (opens in a new tab), Quarterly Report on Form 10-Q (opens in a new tab) and other filings (opens in a new tab) with the U.S. Securities and Exchange Commission. Readers should not place undue reliance on forward-looking statements. Statements speak only as of the date presented, and BGLC undertakes no obligation to update them except as required by law.

Information on this website is a summary and is qualified by BGLC's SEC filings. Website information is not incorporated by reference into any SEC filing unless expressly stated otherwise.

No offer or solicitation

This website is provided for general corporate information only. Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy any security, and no offer or sale will be made except pursuant to applicable securities laws and the relevant offering documents, if any.

Medical and diagnostic information

Content concerning screening, molecular monitoring, laboratory workflows and other health technologies is general information only. It is not medical advice, a diagnosis or a recommendation for treatment, and it does not replace evaluation by a qualified healthcare professional. Test performance, clinical utility, regulatory status, permitted use and availability depend on the specific product, indication and jurisdiction. Page-specific limitations appear near relevant technical descriptions.

Website summaries, dates and historical materials

Website summaries do not replace BGLC's filed disclosures. If a summary differs from an SEC filing, the filed document controls. Historical releases and technical statements speak only as of their original publication dates and should be read with later filings and developments. BGLC does not undertake to update historical material except as required by law.

External links

Links to third-party websites are provided for convenience. BGLC does not control those sites and does not adopt, continuously review or endorse their content. Visiting an external site is subject to that site's own terms and privacy practices.

Privacy

This public corporate website does not ask visitors to submit patient or clinical data. How BGLC handles personal data, including your rights under the Personal Data Protection Act 2010, is set out in the privacy notice (English and Bahasa Malaysia).

Nasdaq-listed company building from established operations toward more precise healthcare in Southeast Asia.

CompanyOverviewBusinessTechnology overviewGenomic screeningVitaGuard MRD
InvestorsInvestor overviewFinancial informationSEC filingsGovernance
Connect[email protected]SEC company page ↗ (opens in a new tab)Legal and disclosuresPrivacy notice

General corporate information only; not an offer, medical advice or a diagnosis. This website contains forward-looking statements that involve risks and uncertainties. Website summaries are qualified by BGLC's SEC filings.

Forward-looking statements →Legal and disclosures →

© 2026 BioNexus Gene Lab Corp. All rights reserved.

Company information current as of July 24, 2026, unless another date is stated.